Late breaking abstracts: Therapies – discovery and development
LB117 – LB120
- LB117: Biological properties of the novel Chk1 inhibitor SAR-020106
- LB118: Combined targeting of Aurora B (AZD1152) and MEK1/2 (AZD6244) kinases leads to enhancement of anti-tumour effects in vivo
- LB119: Phase I evaluation of radioimmunotherapy with 131I-CHT25 in patients with refractory IL2-receptor-expressing lymphomas
- LB120: Construction and characterisation of novel fusion toxin targeted to cancer (DT-SCF)
